The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model-Reference-Cited by-同舟云学术

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model

Published:2016-03-16 Issue:330 Volume:8 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Kirkpatrick Beth D.¹,Whitehead Stephen S.²,Pierce Kristen K.¹,Tibery Cecilia M.³,Grier Palmtama L.³,Hynes Noreen A.⁴,Larsson Catherine J.¹,Sabundayo Beulah P.³,Talaat Kawsar R.³,Janiak Anna³,Carmolli Marya P.¹,Luke Catherine J.⁴,Diehl Sean A.¹,Durbin Anna P.³

Affiliation:

1. Vaccine Testing Center, Department of Medicine, University of Vermont College of Medicine, Burlington, VT 05401, USA.

2. National Institutes of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.

3. Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.

4. Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Abstract

A controlled dengue human challenge model may determine whether to evaluate candidate dengue vaccines in large efficacy trials.

Funder

National Institutes of Allergy and Infectious Diseases Intramural Research Program

NIH

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference35 articles.

1. The global distribution and burden of dengue

2. Evidence That Maternal Dengue Antibodies Are Important in the Development of Dengue Hemorrhagic Fever in Infants

3. A Prospective Study of Dengue Infections in Bangkok

4. Antibodies Determine Virulence in Dengue

5. Dengue Virus Replication Enhancement in Peripheral Blood Leukocytes from Immune Human Beings

Cited by 213 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune Response in Dengue Fever and Clinical Implications;Mosquito-Borne Tropical Diseases [Working Title];2024-08-27

2. Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial;The Lancet Infectious Diseases;2024-08

3. Immune responses and severe dengue: what have we learned?;Current Opinion in Infectious Diseases;2024-07-24

4. Subgenomic flavivirus RNA as key target for live-attenuated vaccine development;Journal of Virology;2024-07-23

5. A pre-vaccination immune metabolic interplay determines the protective antibody response to a dengue virus vaccine;Cell Reports;2024-07